New imaging study for advanced breast cancer withdrawn before starting
NCT ID NCT04273555
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study planned to test whether a special type of PET/MRI scan could detect early signs that targeted therapy is working in people with stage IV HER2+ breast cancer. It was designed for adults aged 18 to 75 with HER2+ metastatic breast cancer. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
Conditions
Explore the condition pages connected to this study.